Johnique T Atkins
Overview
Explore the profile of Johnique T Atkins including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
291
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Atkins J, George G, Hess K, Marcelo-Lewis K, Yuan Y, Borthakur G, et al.
Br J Cancer
. 2020 Sep;
123(10):1496-1501.
PMID: 32868897
Background: Our objective was to determine the correlation between preclinical toxicity found in animal models (mouse, rat, dog and monkey) and clinical toxicity reported in patients participating in Phase 1...
2.
Cox V, Bhosale P, Varadhachary G, Wagner-Bartak N, Glitza I, Gold K, et al.
Radiology
. 2017 Apr;
283(2):314-340.
PMID: 28418819
The field of cancer genomics is rapidly evolving and has led to the development of new therapies. Knowledge of commonly involved cellular pathways and genetic mutations is now essential for...
3.
Wheler J, Atkins J, Janku F, Moulder S, Stephens P, Yelensky R, et al.
Oncoscience
. 2016 Aug;
3(5-6):164-72.
PMID: 27489863
There is limited data on co-expression of FGFR/FGR amplifications and PI3K/ AKT/mTOR alterations in breast cancer. Tumors from patients with metastatic breast cancer referred to our Phase I Program were...
4.
Fujii T, Khawaja M, DiNardo C, Atkins J, Janku F
Discov Med
. 2016 Jun;
21(117):373-80.
PMID: 27355333
Isocitrate dehydrogenase (IDH) is an essential enzyme for cellular respiration in the tricarboxylic acid (TCA) cycle. Recurrent mutations in IDH1 or IDH2 are prevalent in several cancers including glioma, acute...
5.
Mengistu B, Ray D, Lockett P, Dorsey V, Phipps R, Subramanian H, et al.
J Oncol Pract
. 2016 Jun;
12(7):e784-91.
PMID: 27328793
Purpose: Long wait times are a primary source of dissatisfaction among patients enrolled in early-phase clinical trials. We hypothesized that an automated patient check-in system with readily available display for...
6.
Singleton P, Moss J, Karp D, Atkins J, Janku F
Cancer
. 2015 Jun;
121(16):2681-8.
PMID: 26043235
Mu opioids are among the most widely used drugs for patients with cancer with both acute and chronic pain as well as in the perioperative period. Several retrospective studies have...
7.
Wheler J, Atkins J, Janku F, Moulder S, Yelensky R, Stephens P, et al.
BMC Cancer
. 2015 May;
15:442.
PMID: 26021831
Background: The presence of multiple molecular aberrations in patients with breast cancer may correlate with worse outcomes. Case Presentations: We performed in-depth molecular analysis of patients with estrogen receptor-positive, HER2-negative,...
8.
Wheler J, Moulder S, Naing A, Janku F, Piha-Paul S, Falchook G, et al.
Oncotarget
. 2014 Jun;
5(10):3029-38.
PMID: 24912489
Background: Since PI3K/AKT/mTOR pathway activation diminishes the effects of hormone therapy, combining aromatase inhibitors (anatrozole) with mTOR inhibitors (everolimus) was investigated. Patients And Methods: We evaluated anastrozole and everolimus in...
9.
Wheler J, Parker B, Lee J, Atkins J, Janku F, Tsimberidou A, et al.
Oncotarget
. 2014 May;
5(9):2349-54.
PMID: 24811890
Our analysis of the tumors of 57 women with metastatic breast cancer with next generation sequencing (NGS) demonstrates that each patient's tumor is unique in its molecular fingerprint. We observed...
10.
Wheler J, Janku F, Falchook G, Jackson T, Fu S, Naing A, et al.
Cancer Chemother Pharmacol
. 2014 Jan;
73(3):495-501.
PMID: 24435060
Purpose: Anti-angiogenic agents combined with histone deacetylase inhibitors act synergistically in vitro and in vivo. We conducted a phase I study of the combination of the anti-VEGF monoclonal antibody bevacizumab...